Fast Market Research recommends "Lebanon Pharmaceuticals & Healthcare Report Q1 2014" from Business Monitor International, now available
Boston, MA -- (SBWIRE) -- 12/20/2013 -- This quarter has seen Lebanon become more attractive to innovative product launches due to more favourable country demographics. However, we highlight that access to medicines will become increasingly difficult due to ongoing sectarian tensions, political instability and the influx of Syrian refugees, putting downward pressure on healthcare services.
Headline Expenditure Projections
- Pharmaceuticals: LBP1,956bn (US$1.30bn) in 2012 to LBP2,056bn (US$1.37bn) in 2013; +5.1% in local currency and +5.2.% in US dollar terms. Forecast broadly in line with Q413.
- Healthcare: LBP4,278bn (US$2.84bn) in 2012 to LBP4,626bn (US$3.08bn) in 2013; +8.1% in local currency and +8.2% US dollar terms. Forecast broadly in line with Q413.
View Full Report Details and Table of Contents
For Q114, Lebanon's Pharmaceutical Risk/Reward Rating (RRR) score is calculated at 54 out of 100, placing the country sixth in the Middle East and Africa region. This score is two points higher than its Q413 score of 52 and previous ranking of eighth. The positive movement is attributed to a higher Country Rewards score based on an upwards revision to population growth in 2013 and the proportion of pensioners in the country.
Key Trends & Developments
In October 2013, Cardiome International AG, a subsidiary of Canadian biopharmaceutical company Cardiome Pharma Corporation, announced it had entered a commercialisation agreement with Lebanese company Algorithm S.A.L. Under the terms of the agreement Algorithm will sell and distribute Cardiome's cardiology drug Brinavess (vernakalant intravenous) in a number of Middle East and North African countries. Brinavess, developed by Merck & Co, has been approved in Europe and the US for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
In the same month, local practitioners were cited by the Daily Star saying that alternative medical treatments such as reiki, acupuncture, homeopathy and Chinese herbal medicine were rapidly growing in popularity in Lebanon, However, these non-mainstream medical treatments are not yet regulated by any state laws or self-regulatory agencies in the country, making it easier for frauds to pose as experts. Another problem with this unregulated segment of medical treatment are advertisements on television for so-called herbal treatments.
BMI Economic View: We project real GDP growth in Lebanon of 1.7% in 2013 and 2.5% in 2014. Elevated political instability and the ongoing political deadlock will contribute to below-potential growth over the coming quarters, with exports and fixed investment to be particularly hard hit.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Sweden Pharmaceuticals & Healthcare Report Q1 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q1 2014
- Nigeria Pharmaceuticals & Healthcare Report Q1 2014
- Romania Pharmaceuticals & Healthcare Report Q1 2014
- Oman Pharmaceuticals & Healthcare Report Q1 2014
- Uzbekistan Pharmaceuticals & Healthcare Report Q1 2014
- Slovenia Pharmaceuticals & Healthcare Report Q1 2014
- Croatia Pharmaceuticals & Healthcare Report Q1 2014
- Latvia Pharmaceuticals & Healthcare Report Q1 2014
- Netherlands Pharmaceuticals & Healthcare Report Q1 2014